Article Text

Download PDFPDF

High-dose intravenous human immunoglobulin in polymyositis resistant to treatment.
  1. S Jann,
  2. S Beretta,
  3. M Moggio,
  4. L Adobbati,
  5. G Pellegrini
  1. Institute of Neurology, University of Milan, Policlinico Hospital, Italy.


    Two patients were treated with treatment-resistant polymyositis with intravenous immunoglobulin over four days at a dose of 0.4 g/kg/day. Clinical recovery followed within two months. Serum creatine kinase (CK) activity decreased to normal, and a clear improvement in muscle strength was observed. One patient showed neither clinical relapses nor increase in serum CK activity after 20 months. The other showed a mild increase in serum CK activity after 24 months and was successfully retreated with intravenous immunoglobulin. There were no significant adverse side effects.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.